Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo.
Parathyroid hormone-related protein (PTHRP) has recently been purified from human tumors associated with the syndrome of humoral hypercalcemia of malignancy. The gene encoding PTHRP has been cloned, and based on predicted amino acid sequence, polypeptides comprising the first 36 [36Tyr(1-36) PTHRP amide] and 74 [(1-74)PTHRP] amino acids have been synthesized. Human (h) PTHRP (1-36) and (1-74) are potent bone-resorbing agents, and are catabolic for bone in vivo when given continuously at high doses. Bovine parathyroid hormone (bPTH) (1-34) is also catabolic for bone at high dose levels, but when given in low doses for weeks to months, it is anabolic. Although PTHRP possess several PTH-like properties in bone, hPTHRP (1-34) is reported to be only weakly anabolic in vivo. As polypeptide length influences PTHRP action, we evaluated hPTHRP(1-74) as an anabolic agent for bone in vivo. Twenty-four 4-week-old male Sprague-Dawley rats were given daily subcutaneous injections of hPTHRP(1-74) (1 and 2 nmol/100 g body weight, bw), bPTH(1-34) (4 nmol/100 g bw) or vehicle. Rats were sacrificed on day 12, and serum calcium, phosphorus, and 1,25 dihydroxyvitamin D and femoral bone dry weight, calcium content, and hydroxyproline content were measured. Serum calcium and phosphorus were equivalent in all groups. A significant increase in dry bone weight was observed in both PTHRP-treated groups compared with controls. PTHRP also caused a significant, dose-dependent increase in bone calcium and hydroxyproline content. Results of these studies indicate that PTHRP (1-74) is anabolic for bone in vivo when administered at low-dosage levels for a prolonged period.
Weir
E C
EC
Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
Terwilliger
G
G
Sartori
L
L
Insogna
K L
KL
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000032:analysis / Q000097:blood; D004305:Dose-Response Relationship, Drug; D006728:Hormones / Q000008:administration & dosage / Q000494:pharmacology*; D006909:Hydroxyproline / Q000032:analysis; D007279:Injections, Subcutaneous; D008297:Male; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010710:Phosphates / Q000097:blood; D011506:Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019379:Teriparatide
D006728:Hormones; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D010710:Phosphates; D011506:Proteins; D019379:Teriparatide; C065305:parathyroid hormone-related protein (1-74); D002117:Calcitriol; D006909:Hydroxyproline; D002118:Calcium